

## Malaria eradication efforts: Progress and obstacles.

Elizabeth Liz\*

Department of Medicine, University of Oxford, UK

### Introduction

Malaria, a life-threatening disease caused by Plasmodium parasites and transmitted through the bites of infected Anopheles mosquitoes, continues to pose a significant global health challenge. Despite substantial progress in reducing the incidence and mortality of malaria over the past two decades, the goal of complete eradication remains elusive. This article explores the progress made in malaria eradication efforts, the strategies employed, and the obstacles that hinder the ultimate goal of a malaria-free world [1, 2].

The establishment of global initiatives such as the Roll Back Malaria Partnership and the Global Fund to Fight AIDS, Tuberculosis, and Malaria has galvanized international efforts and funding. Between 2000 and 2020, over \$3 billion was invested annually in malaria control and elimination efforts [3, 4].

The development and deployment of innovative tools have been critical in the progress against malaria. These include Rapid Diagnostic Tests (RDTs), which allow for quick and accurate diagnosis, and the introduction of the RTS,S/AS01 malaria vaccine (Mosquirix), which provides partial protection against Plasmodium falciparum, the most deadly malaria parasite [5, 6].

Effective vector control measures, such as ITNs and IRS, remain the cornerstone of malaria prevention. In recent years, new approaches like the use of Long-Lasting Insecticidal Nets (LLINs) and targeted IRS campaigns have shown promise in reducing mosquito populations and interrupting transmission [7, 8].

Weak health systems in many malaria-endemic countries hinder the effective delivery of interventions. Challenges include inadequate infrastructure, limited healthcare workforce, and poor access to healthcare services, especially in rural and remote areas. Malaria is closely linked to poverty, and addressing the socioeconomic determinants of health is essential for sustainable malaria control. Additionally, environmental factors such as climate change and deforestation can influence mosquito breeding and transmission patterns, complicating eradication efforts [9, 10].

### Conclusion

Malaria eradication is an ambitious but achievable goal. The progress made over the past two decades demonstrates that with the right strategies, resources, and commitment, significant gains can be made. However, overcoming the obstacles to eradication requires sustained effort, innovation, and global collaboration. Addressing drug and insecticide resistance, closing funding gaps, strengthening health systems, and tackling the broader socioeconomic and environmental determinants of malaria are essential steps towards a malaria-free world.

### References

1. Healer J, Cowman AF, Kaslow DC, et al. Vaccines to accelerate malaria elimination and eventual eradication. *Cold Spring Harb Perspect Med*. 2017;7(9):a025627.
2. Cowman AF, Healer J, Marapana D, et al. Malaria: biology and disease. *Cell*. 2016;167(3):610-24.
3. Aderinto N, Olatunji G, Kokori E, et al. A perspective on Oxford's R21/Matrix-M™ malaria vaccine and the future of global eradication efforts. *Malar J*. 2024;23(1):16.
4. Kokori E, Olatunji G, Akinboade A, et al. Triple artemisinin-based combination therapy (TACT): advancing malaria control and eradication efforts. *Malar J*. 2024;23(1):25.
5. Nissan H, Ukawuba I, Thomson M. Climate-proofing a malaria eradication strategy. *Malar J*. 2021;20:1-6.
6. Fornace KM, Diaz AV, Lines J, et al. Achieving global malaria eradication in changing landscapes. *Malar J*. 2021;20(1):69.
7. Cortés A, Deitsch KW. Malaria epigenetics. *Cold Spring Harb Perspect Med*. 2017;7(7):a025528.
8. González-Silva M, Rabinovich NR. Some lessons for malaria from the Global Polio Eradication Initiative. *Malar J*. 2021;20(1):210.
9. Newby G, Bennett A, Larson E, et al. The path to eradication: a progress report on the malaria-eliminating countries. *Lancet*. 2016;387(10029):1775-84.
10. Basu S, Sahi PK. Malaria: an update. *Indian J Pediatr*. 2017;84:521-8.

---

\*Correspondence to: Elizabeth Liz, Department of Medicine, University of Oxford, UK. E-mail: liz3@trop.ac.uk

Received: 27-Oct-2023, Manuscript No. AAJIDMM-24-142937; Editor assigned: 30-Oct-2023, PreQC No. AAJIDMM-24-142937 (PQ); Reviewed: 13-Nov-2023, QCNo. AAJIDMM-24-142937; Revised: 15-Nov-2023, Manuscript No. AAJIDMM-24-142937 (R); Published: 20-Nov-2023, DOI:10.35841/aajidmm-7.6.176